A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of the long-term use of
pregabalin at doses up to 600 mg/day in patients with painful diabetic peripheral neuropathy
who have completed 13 weeks of dosing in Study A0081163
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.